Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Skin fluid may reveal heart failure secrets without needles

NCT ID NCT06200636

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether signs of heart failure can be found in fluid just under the skin, called dermal interstitial fluid. Researchers tested 20 heart failure patients using a special device to collect this fluid during exercise. The goal was to see if these skin-based markers could one day help track the disease without needing blood draws.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Apr 2024

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject suffers from heart failure (according to ESC 2021 Heart Failure Guidelines). * Age of subject is ≥18 years. * Subject is female or male. * Signed written informed consent. * For female subjects: 1. Confirmed post-menopausal state, defined as amenorrhea for at least 12 months, or 2. If being of childbearing potential: 1. Negative highly sensitive urine or serum pregnancy test before inclusion, and 2. Practicing a highly effective birth control method (failure rate of less than 1%): 1. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral/intravaginal/ transdermal), or 2. progestogen-only hormonal contraception associated with inhibition of ovulation (oral/injectable/implantable), or 3. intrauterine device (IUD), or 4. intrauterine hormone-releasing system (IUS), or 5. bilateral tubal occlusion, or 6. vasectomised partner, or 7. heterosexual abstinence. * Subject is capable to perform cardiopulmonary exercise testing. Exclusion Criteria: * Subject is breastfeeding. * Subject suffers from an addiction or from a disease that prevents the subject from recognizing nature, scope, and consequences of the study. * Subject is treated with immunosuppressive drugs at enrolment. * Subject requires renal replacement therapy. * Subject has a known colonisation or infection with multi-drug-resistant pathogens. * Subject has an open wound in or near the sampling area. * Subject has any type of tattoo or piercing anywhere in or near the sampling area. * Subject shows an inability to comply with all the study procedures and follow-up visits. * Subject is unwilling to consent to saving and propagation of pseudonymised medical data for study reasons. * Subject is legally detained in an official institution. * Subject is dependent on the sponsor, the investigator or the study sites. * Subject participates in a study according to AMG/CTR that investigates immunosuppressive or anticoagulant drugs at the time of this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Deutsches Herzzentrum der Charité

    Berlin, State of Berlin, 13353, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.